Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135720 · ClinicalTrials.gov registry record · Phase 2
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00135720: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00135720 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00135720, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to find out about the effectiveness and the safety of an investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus vulgaris is a potentially life threatening blistering condition that currently has no cure. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Etanercept has been approved by the FDA to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriasis, but not pemphigus vulgaris.
Interventions
- DRUG Enbrel (Etanercept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135720
The ClinicalTrials.gov registry entry for NCT00135720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enbrel (Etanercept) is the first listed.
NCT00135720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135720 about?
NCT00135720 is a clinical study titled "Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris". The purpose of the study is to find out about the effectiveness and the safety of an investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus vulgaris is a potentially life threatening blistering condition that currently has no cure. An investigational drug is one that...
What is the current status of trial NCT00135720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-06. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00135720?
The interventions under investigation include: Enbrel (Etanercept) (DRUG).
Who is sponsoring clinical trial NCT00135720?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.